首页 > 市场调查报告书 > 医疗设备

市场调查报告书

商品编码

1542945

全球子宫内避孕器 (IUD) 市场 - 2024-2031

Global Intrauterine Contraceptive Devices (IUD) Market - 2024-2031

出版日期: 2024年08月26日 | 出版商:

DataM Intelligence | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

报告概述

2023年，全球子宫内避孕器（IUD）市场规模达31亿美元，预计2031年将达到44.5亿美元，2024-2031年预测期间复合年增长率为4.7%。

子宫内避孕器是一种用于节育的小型塑胶 T 形装置。它被插入子宫并停留以防止怀孕。子宫内避孕器可防止精子使卵子受精，并防止受精卵植入子宫。子宫内避孕器在预防和治疗子宫内膜癌和其他疾病的应用也正在研究中。

子宫内避孕器是当今最有效的避孕形式之一，其失败率与各种形式的绝育手术相似。子宫内避孕器有许多好处，包括功效、易用性、可逆性和患者满意度，特别是长期使用的时间和成本。本活动回顾了子宫内避孕器放置和取出的适应症、禁忌症、风险和益处。这项活动还将详细介绍跨专业团队在为接受子宫内避孕器放置和取出的患者提供最佳护理方面的作用。

市场动态：

司机

病毒感染流行率不断上升

子宫内避孕器（IUD）市场的需求是由多种因素所驱动的。人们意识的提高推动了市场的成长。此外，技术进步和政府措施将推动子宫内避孕器（IUD）市场的需求。例如，据联合国称，截至 2022 年 2 月，全球有 1.61 亿人使用子宫内避孕器 (IUD) 作为避孕形式，使其成为全球最常见的方法之一。根据疾病预防控制中心(CDC) 的数据，截至2023 年12 月，在美国，20.4% 有性经验的女性曾经使用过子宫内避孕器。使用者中，有14% 使用过子宫内避孕器，高于2002 年为2.4%。 49 岁之间的女性使用子宫内避孕器的比例最低，为5-6%。

此外，根据 nih.gov 2023 年 7 月发布的一篇文章，子宫内避孕器避孕方法的使用差异很大。东亚、东南亚和北非为 18%，突尼斯为 27.8%，埃及为 36.1%。儘管现代避孕方法的使用率几乎增加了两倍； 2005 年至 2019 年间，衣索比亚已婚妇女的比例从 14% 增加到 41%，子宫内避孕器对避孕方法组合的贡献可以忽略不计。子宫内避孕器的使用率从亚的斯亚贝巴的 5.2% 到甘贝拉地区的 0.4% 到衣索比亚索马利亚地区的零。

限制

子宫内避孕器相关的高成本以及子宫内避孕器引起的副作用等因素预计将阻碍市场的发展。使用子宫内避孕器的女性可能会出现副作用，例如月经週期不规则、经期出血增加和经期痉挛恶化。在少数情况下，它可能会导致子宫外孕和骨盆疼痛。

细分市场分析

全球子宫内避孕器市场根据类型、最终用户和地区进行细分。

铜子宫内避孕器占据子宫内避孕器市占率约45.8%

预计铜子宫内避孕器细分市场将在预测期内占据最大的市场份额。在这一领域，政府监管的发展以及私营製造商用于研究工作的资金不断增加将推动该市场的发展。

非激素铜子宫内避孕器是一种小型塑胶装置，其框架上缠绕着铜线。它被插入子宫（子宫），子宫内避孕器不断释放少量的铜。含铜子宫内避孕器的避孕效果超过 99%，可持续使用长达 5 - 10 年（取决于类型）。如果在 40 岁或以上时插入含铜子宫内避孕器，则可在停经前避孕。

例如，2023 年 10 月，Sebela Pharmaceuticals 旗下的 Sebela Women's Health Inc. 宣布了来自研究性铜 175 mm2 子宫内避孕器 (IUD) 的关键 3 期开放标籤研究的更多积极资料。最近三届妇女健康科学大会上发表的资料为研究性下一代无激素子宫内避孕器提供了进一步的支持，如其关键的 3 期试验所示。无激素铜 175 mm2 IUD 具有由镍钛诺製成的柔性框架，这种材料具有超弹性特性，可将铜策略性地放置在输卵管口和子宫颈内口附近，以实现近端效果。

市场地域占有率

北美约占子宫内避孕器市场占有率的48.6%

预计北美地区将在预测期内占据最大的市场份额。该地区人们的意识不断增强，有助于推动市场发展。

例如，2022 年8 月，美国食品药物管理局(FDA) 批准了一份补充新药申请，将Mirena（左炔诺孕酮子宫内缓释系统）52 mg 子宫内避孕器(IUD) 延长一年，从而延长了使用子宫内避孕器(IUD) 的数量。此次批准是在一项 3 期试验之后进行的，该试验分析了 Mirena 对 362 名使用该产品超过 5 年的女性的有效性。使用6至8年，避孕效果超过99%，且未发现新的安全性发现。 Mirena 将荷尔蒙左旋诺孕酮释放到子宫中以防止怀孕，并且可以治疗采取子宫内避孕的女性 5 年的月经过多。

An intrauterine device is a small plastic T-shaped device used for birth control. It is inserted into the uterus where it stays to prevent pregnancy. Intrauterine devices prevent sperm from fertilizing an egg and prevent fertilized eggs from implanting in the uterus. The use of intrauterine devices is also being studied in the prevention and treatment of endometrial cancer and other conditions.

Intrauterine devices are one of the most effective forms of contraception available today, with rates of failure similar to various forms of sterilization. There are many benefits of IUDs, including efficacy, ease of use, reversible nature, and patient satisfaction, especially with time commitment for long-term use and cost. This activity reviews the indications, contraindications, risks, and benefits of intrauterine device placement and removal. This activity will also detail the role of the interprofessional team in providing patients who undergo intrauterine device placement and removal with the best possible care.

Market Dynamics: Drivers

Increasing prevalence of viral infections

The demand for the intrauterine contraceptive devices (IUD) market is driven by multiple factors. The increase in awareness among people propels the market growth. Furthermore, the demand for the intrauterine contraceptive devices (IUD) market will be fueled by technological advancements and government initiatives. For instance, according to the United Nations, as of February 2022, the United Nations reported that 161 million people worldwide use intrauterine devices (IUDs) as a form of contraception, making it one of the most common methods globally. In the United States, 20.4% of sexually experienced women have ever used an IUD, according to the CDC as of December 2023. In 2016, 14% of contraceptive users between the ages of 15 and 44 in the U.S. used an IUD, up from 2.4% in 2002. Women between the ages of 25 and 29 had the highest rates of IUD use at 19%, while those between 15 and 19 and 45 and 49 had the lowest rates at 5-6%.

Moreover, according to an article posted by nih.gov, in July 2023, the use of an IUD contraceptive method varies widely. 18% in Eastern and southeastern Asia, and Northern Africa, while it is 27.8% in Tunisia and 36.1% in Egypt. Even though the use of modern contraceptive methods has nearly tripled; increasing from 14% to 41% between 2005 and 2019 among married women in Ethiopia, the contribution of an IUD to the method mix is negligible. The utilization of an IUD varies from 5.2% in Addis Ababa to 0.4% in the Gambella region to null in the Somali region of Ethiopia.

Restraints

Factors such as high costs associated with IUDs and side effects caused due to IUDs are expected to hamper the market. Women who use IUDs may experience side effects such as irregular menstrual cycle, increased period bleeding, and worsening of period cramps. In a few cases, it may lead to ectopic pregnancies and pelvic pain.

Market Segment Analysis

The global intrauterine contraceptive devices market is segmented based on type, end-user, and region.

The segment copper IUD accounted for approximately 45.8% of the intrauterine contraceptive devices market share

The copper IUD segment is expected to hold the largest market share over the forecast period. In this segment, the development of government regulation, and rising funds for private manufacturers for research work would drive this market.

The non-hormonal copper IUD is a small plastic device with copper wire coiled (wrapped) around the frame. It is inserted into the uterus (womb) where the IUD constantly releases a small amount of copper. The copper IUDs are more than 99% effective at preventing pregnancy and can last for up to 5 - 10 years (depending on the type). A copper IUD can be used for contraception until menopause if inserted when one is 40 years of age or older.

For instance, in October 2023, Sebela Women's Health Inc., a part of Sebela Pharmaceuticals, announced additional positive data from the pivotal Phase 3 open-label study of the investigational Copper 175 mm2 intra-uterine device (IUD). The data presented at three recent women's health scientific congresses provide further support for the investigational, next-generation, hormone-free IUD as exhibited in its pivotal phase 3 trial. The hormone-free Copper 175 mm2 IUD has a flexible frame made of nitinol, a material that has superelastic properties and allows for the copper to be strategically placed near the Ostia of the fallopian tubes and the internal os of the cervix for proximal effect.

Market Geographical Share

North America accounted for approximately 48.6% of the intrauterine contraceptive devices market share

North America region is expected to hold the largest market share over the forecast period. The growing awareness among people, in this region, helps to propel the market.

For instance, in August 2022, the US Food and Drug Administration (FDA) approved a supplemental New Drug Application for an extension of Mirena (levonorgestrel-releasing intrauterine system) 52 mg Intrauterine Device (IUD) for an additional year, extending the number of years it can be used to prevent pregnancy to 8 years. The approval follows a phase 3 trial which analyzed the effectiveness of Mirena in 362 women who have used the product for over 5 years. Contraceptive efficacy was over 99% from 6 to 8 years of use, and no new safety findings were found. Mirena releases the hormone levonorgestrel into the uterus to prevent pregnancy and can treat heavy periods for 5 years in women who take intrauterine contraception.

Market Segmentation

By Type

Hormonal IUD
Copper IUD

By End-User

Hospitals
Gynaecology Clinics
Community Healthcare Centers
Others

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
South America
Brazil
Argentina
Rest of South America
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Middle East and Africa

Market Competitive Landscape

The major global players in the global intrauterine contraceptive devices (IUD) market include Teva Pharmaceuticals, Bayer, Pregna, OCON Medical, Eurogine, SMB Corporation, Actavis, Agile, Besins Healthcare, and Pfizer among others.

Key Developments

In July 2024, 3Daughters, a clinical development company dedicated to advancing women's healthcare, announced the successful completion of an oversubscribed seed financing round, raising $4.7 million. This round saw participation from existing investors including Thairm Bio, Argosy Foundation, Wexford Science and Technology, UMass Amherst, and new undisclosed investors.
In November 2023, Bayer and CrossBay Medical announced a development and licensing agreement to create a single-handed inserter for intrauterine systems (IUS), integrating CrossBay's CrossGlide technology with Bayer's hormonal IUD portfolio. The new inserter, using CrossGlide technology, aims to potentially improve the comfort of intrauterine placement, and might reduce discomfort during the insertion process. This could also shorten the procedure time required by healthcare professionals.

Why Purchase the Report?

To visualize the global intrauterine contraceptive devices market segmentation based on type, end-user, and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development
Excel data sheet with numerous data points of global intrauterine contraceptive devices market level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping is available in Excel consisting of key products of all the major players.

The global intrauterine contraceptive devices market report would provide approximately 51 tables, 54 figures, and 181 Pages.

Target Audience 2024

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Type
3.2. Snippet by End-User
3.3. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing Awareness Among People
  - 4.1.1.2. Technological Advancements
  - 4.1.1.3. Government Initiatives

5. Restraints

5.1. High Costs Associated
5.2. Side Effects Caused due to IUDs

6. Opportunity

7. Impact Analysis

8. Industry Analysis

8.1. Porter's Five Force Analysis
8.2. Supply Chain Analysis
8.3. Pricing Analysis
8.4. Regulatory Analysis
8.5. Unmet Needs
8.6. PESTEL Analysis
8.7. Patent Analysis
8.8. SWOT Analysis

9. By Type

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.1.2. Market Attractiveness Index, By Drug Type
9.2. Hormonal IUD*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Copper IUD

10. By End-User

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.1.2. Market Attractiveness Index, By End-User
10.2. Hospitals*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Specialty Clinics
10.4. Homecare
10.5. Others

11. By Region

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.2.5.1. The U.S.
  - 11.2.5.2. Canada
  - 11.2.5.3. Mexico
11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.3.5.1. Germany
  - 11.3.5.2. UK
  - 11.3.5.3. France
  - 11.3.5.4. Italy
  - 11.3.5.5. Spain
  - 11.3.5.6. Rest of Europe
11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.4.5.1. Brazil
  - 11.4.5.2. Argentina
  - 11.4.5.3. Rest of South America
11.5. Asia-Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.5.5.1. China
  - 11.5.5.2. India
  - 11.5.5.3. Japan
  - 11.5.5.4. South Korea
  - 11.5.5.5. Rest of Asia-Pacific
11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis

13. Company Profiles

13.1. Teva Pharmaceuticals*
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
13.2. Bayer
13.3. Pregna
13.4. OCON Medical
13.5. Eurogine
13.6. SMB Corporation
13.7. Actavis
13.8. Agile
13.9. Besins Healthcare
13.10. Pfizer (*LIST NOT EXHAUSTIVE)